The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Open accessAbstract
Introduction: Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods: We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results: Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion: Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“an 8-year follow-up study of 599 volunteers (average age 70 years) in Australia found that cognitively normal PET amyloid-positive people had an elevated risk of developing Alzheimer's disease compared with amyloid negative (17·7% vs 8·1%; OR 2·4, 95% CI 1·5–4·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma Aβ measures now show promise [202,203].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The cited source says what the claim attributes to it.
In the citing paper
“While imaging/CSF biomarker data on subsets of individuals from well-designed community-based cohorts would provide additional research value, incorporating biomarkers on a large scale in many settings will require low-cost and minimally invasive biomarkers (e.g., blood or saliva) that are now emerging [202–205].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Over 80% of the 266 people who were PET amyloid-positive did not go onto develop a cognitive impairment within 8 years, showing positive status does not predict impairment for most people in a timeframe that might be a useful prognostic window.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Follow-up at 5 years of amyloid-positive participants with normal cognition or mild cognitive impairment versus amyloid negative people found the same pattern of increased risk (2·6, 1·4–4·9).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Risk also increases per 1 year of age (HR 1·05, 95% CI 0·55–2·0/year), and APOEε4 status (2·6, 1·4–5·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [8]
In the citing paper
“Recent studies demonstrate the ability to detect CNS Aβ deposition via the use of plasma assessment of Aβ species”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Ovod et al., 2017
In the citing paper
“Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
In the citing paper
“In mass spectrometry–based techniques, 2 recent studies have provided overall better accuracies for plasma Aβ42/Aβ40 (AUC, 0.84-0.97 depending on population and reference standard).19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“3%, respectively, when confirmed by postmortem histopathology [4].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citationAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Cited by
Sorted by citations
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationDementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“These results are similar to other amyloid blood biomarkers 189,190 and harmonisation to a common reference standard is now vital.”
RetractedScheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Self-citationRevised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Mielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease
Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., Cao, Y., & Li, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57078 · Cited by 689
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494
Self-citationChatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437
Self-citationBiomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Zetterberg, H., & Bendlin, B. B. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 408
Blood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 372
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 351
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
Verberk, I. M. W., Slot, R. E., Verfaillie, S. C. J., Heijst, H., Prins, N. D., van Berckel, B. N. M., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2018) · Annals of Neurology · doi:10.1002/ana.25334 · Cited by 315
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Self-citationChen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 302
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Blood-based molecular biomarkers for Alzheimer’s disease
Zetterberg, H., & Burnham, S. C. (2019) · Molecular Brain · doi:10.1186/s13041-019-0448-1 · Cited by 259
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Verberk, I. M. W., Misdorp, E. O., Koelewijn, J., Ball, A. J., Blennow, K., Dage, J. L., Fandos, N., Hansson, O., Hirtz, C., Janelidze, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12510 · Cited by 243
Molecular biomarkers of Alzheimer's disease: progress and prospects
Lashley, T., Schott, J. M., Weston, P. S. J., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M. S., Toombs, J., Rohrer, J. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031781 · Cited by 251
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Zetterberg, H., & Blennow, K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00430-x · Cited by 219
West, T., Kirmess, K. M., Meyer, M. R., Holubasch, M. S., Knapik, S. S., Hu, Y., Contois, J. H., Jackson, E. N., Harpstrite, S. E., Bateman, R. J., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00451-6 · Cited by 222
Self-citationSafiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 273
Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
Lim, C. Z. J., Zhang, Y., Chen, Y., Zhao, H., Stephenson, M. C., Ho, N. R. Y., Chen, Y., Chung, J., Reilhac, A., Loh, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09030-2 · Cited by 209
Early-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E. A., Kurup, J. T., Beecham, G. W., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 210
Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke, J. D., Pérez‐Grijalba, V., Fandos, N., Fowler, C. J., Villemagne, V. L., Masters, C. L., Pesini, P., & Sarasa, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009240 · Cited by 202
Amyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
Diagnostic biomarkers of Alzheimer’s disease: A state-of-the-art review
Khoury, R., & Ghossoub, E. (2019) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2019.100005 · Cited by 200
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
Li, Y., Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Weiner, M. W., Shaw, L. M. J., Masters, C. L., Fowler, C. J., Trojanowski, J. Q., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013211 · Cited by 201
Self-citationCullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., et al. (2020) · Nature Aging · doi:10.1038/s43587-020-00003-5 · Cited by 187
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S. G., Suárez‐Calvet, M., Karikari, T. K., Schöll, M., Joie, R. L., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 185
Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12395 · Cited by 188
Vergallo, A., Mégret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., Vos, A. D., Habert, M., Potier, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.009 · Cited by 178
Late-onset vs nonmendelian early-onset Alzheimer disease
Reitz, C., Rogaeva, E. A., & Beecham, G. W. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000512 · Cited by 184
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 166
Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01117-1 · Cited by 151
Self-citationClinical Research on Alzheimer’s Disease: Progress and Perspectives
Sun, B., Li, W., Zhu, C., Jin, W., Zeng, F., Liu, Y.-H., Bu, X., Zhu, J., Yao, X., & Wang, Y. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0249-z · Cited by 171
Pais, M. V., Forlenza, O. V., & Diniz, B. S. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230029 · Cited by 184
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
Li, D., & Mielke, M. M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00164-5 · Cited by 147
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Early-stage Alzheimer disease: getting trial-ready
Aisen, P. S. S., Jimenez‐Maggiora, G. A., Rafii, M. S., Walter, S., & Raman, R. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00645-6 · Cited by 157
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 154
Lü, Y., Liu, C., Yu, D., Fawkes, S. A., Ma, J., Zhang, M., & Li, C. (2021) · BMC Geriatrics · doi:10.1186/s12877-020-01948-3 · Cited by 157
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 152
The Past and the Future of Alzheimer’s Disease Fluid Biomarkers
Blennow, K., & Zetterberg, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170773 · Cited by 154
Plasma Amyloid-β (Aβ 42 ) Correlates with Cerebrospinal Fluid Aβ 42 in Alzheimer’s Disease
Teunissen, C. E., Chiu, M., Yang, C., Yang, S., Scheltens, P., Zetterberg, H., & Blennow, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170784 · Cited by 150
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 150
Biosensors for Alzheimer's disease biomarker detection: A review
Shui, B., Tao, D., Florea, A., Cheng, J., Zhao, Q., Gu, Y., Li, W., Jaffrezic-Renault, N. J., Mei, Y., & Guo, Z. (2018) · Biochimie · doi:10.1016/j.biochi.2017.12.015 · Cited by 139
Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 148
Janelidze, S., Barthélemy, N. R., Salvadó, G., Schindler, S. E., Palmqvist, S., Mattsson, N., Braunstein, J. B., Ovod, V., Bollinger, J. G., He, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2619 · Cited by 141
Self-citationMartins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Blood-based biomarkers for Alzheimer’s disease—An update
Zetterberg, H. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.025 · Cited by 128
Kirmess, K. M., Meyer, M. R., Holubasch, M. S., Knapik, S. S., Hu, Y., Jackson, E. N., Harpstrite, S. E., Verghese, P. B., West, T., Fogelman, I., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.05.011 · Cited by 128
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Hanon, O., Vidal, J., Lehmann, S., Bombois, S., Allinquant, B., Tréluyer, J., Gelé, P., Delmaire, C., Blanc, F., Mangin, J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.01.004 · Cited by 123
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Jonaitis, E. M., Janelidze, S., Cody, K. A., Langhough, R., Du, L., Chin, N. A., Mattsson-Carlgren, N., Hogan, K. J., Christian, B. T., Betthauser, T. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad057 · Cited by 124
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Alzheimer disease blood biomarkers: considerations for population-level use
Mielke, M. M., & Fowler, N. R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00989-1 · Cited by 137
Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders
Morozova, A. Y., Zorkina, Y., Abramova, O. V., Pavlova, O., Ka, P., Soloveva, K., Volkova, M., Alekseeva, P. A., Andryshchenko, A., Kostyuk, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031217 · Cited by 132
Hu, Y., Kirmess, K. M., Meyer, M. R., Rabinovici, G. D., Gatsonis, C., Siegel, B. A., Whitmer, R. A., Apgar, C., Hanna, L., Kanekiyo, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8392 · Cited by 120
Self-citationDiet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis
Hill, E., Goodwill, A. M., Gorelik, A., & Szoeke, C. E. I. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.008 · Cited by 120
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 124
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Self-citationPredictive Value of Routine Peripheral Blood Biomarkers in Alzheimer’s Disease
Dong, X., Nao, J., Shi, J., & Zheng, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00332 · Cited by 110
Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Schöll, M., Zetterberg, H., Blennow, K., Chen, C., & Lai, M. K. P. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327370 · Cited by 111
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 107
Keshavan, A., Pannee, J., Karikari, T. K., Lantero‐Rodriguez, J., Ashton, N. J., Nicholas, J. M., Cash, D. M., Coath, W., Lane, C., Parker, T. D., et al. (2020) · Brain · doi:10.1093/brain/awaa403 · Cited by 110
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers
Kim, K., Lee, C. H., & Park, C. B. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00107d · Cited by 101
Meyer, S. D., Schaeverbeke, J. M., Verberk, I. M. W., Gille, B., Schaepdryver, M. D., Luckett, E. S., Gabel, S., Bruffaerts, R., Mauroo, K., Thijssen, E. H., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00728-w · Cited by 102
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
McDermott, B., Porter, E., Hughes, D., McGinley, B., Lang, M. J., O’Halloran, M., & Jones, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180391 · Cited by 105
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L. A., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 99
Self-citationPlasma amyloid beta levels are associated with cerebral amyloid and tau deposition
Risacher, S. L., Fandos, N., Romero, J., Sherriff, I., Pesini, P., Saykin, A. J., & Apostolova, L. G. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.05.007 · Cited by 96
Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Saridin, F. N., Reilhac, A., Robins, E. G., Nai, Y., Vrooman, H. A., Hilal, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12332 · Cited by 97
From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease
Zetterberg, H., & Blennow, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179926 · Cited by 98
Assessment of Plasma Amyloid-β42/40and Cognitive Decline Among Community-Dwelling Older Adults
Giudici, K. V., Barreto, P. D. S., Guyonnet, S., Li, Y., Bateman, R. J., Vellas, B. J., & MAPT/DSA Group (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.28634 · Cited by 94
Self-citationMiao, R., Chen, H.-Y., Gill, S., Naude, J., Smith, E., & Ismail, Z. (2021) · medRxiv · doi:10.1177/08919887211016068 · Cited by 93
Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 94
Clinical performance and robustness evaluation of plasma amyloid‐β 42/40 prescreening
Rabe, C., Bittner, T., Jethwa, A., Suridjan, I., Manuilova, E., Friesenhahn, M. J., Stomrud, E., Zetterberg, H., Blennow, K., Hansson, O., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12801 · Cited by 88
Metadata
- Authors
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 13
- Issue
- 8
- Pages
- 841-849
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5567785
- OpenAlex
- W2736518852
- Cited by
- 585
- References
- 18
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 74 · 2023: 65 · 2022: 84 · 2021: 85 · 2020: 70 · 2019: 66 · 2018: 47 · 2017: 2
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, plasma amyloid-beta
- MeSH terms
- Aged, Amyloidosis, Chromatography, Liquid, Humans, Isotope Labeling, Kinetics, Peptide Fragments, Prospective Studies, ROC Curve, Mass Spectrometry, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Area Under Curve, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
